RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive ...

Recursion Pharmaceuticals (RXRX) closed at $4.05 in the latest trading session, marking a +2.02% move from the prior day. Elsewhere, the Dow saw a downswing of 0.36%, while the tech-heavy Nasdaq ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Recursion Pharmaceuticals (RXRX) is back on traders’ screens after a sharp daily move, with the share price closing at ...

Recursion Pharmaceuticals (RXRX) closed at $3.18 in the latest trading session, marking a -1.85% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.45% for the ...

Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...

Recursion Pharmaceuticals shares have been a disaster for investors who've been holding them. After falling by more than half in less than a year, though, the stock could be a bargain now. Here's a ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

September 11, 2026 16:26 ET Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, ...